{
    "q": [
        {
            "docid": "2459654_31",
            "document": "Pseudomonas aeruginosa . Mechanisms underlying antibiotic resistance have been found to include production of antibiotic-degrading or antibiotic-inactivating enzymes, outer membrane proteins to evict the antibiotics and mutations to change antibiotic targets. Presence of antibiotic-degrading enzymes such as extended-spectrum \u03b2-lactamases like PER-1, PER-2, VEB-1, AmpC cephalosporinases, carbapenemases like serine oxacillinases, metallo-b-lactamases, OXA-type carbapenemases, aminoglycoside-modifying enzymes, among others have been reported. \"P. aeruginosa\" can also modify the targets of antibiotic action, for example methylation of 16S rRNA to prevent aminoglycoside binding and modification of DNA, or topoisomerase to protect it from the action of quinolones. \"P. aeruginosa\" has also been reported to possess multidrug efflux pumps like AdeABC and AdeDE efflux systems that confer resistance against number of antibiotic classes. An important factor found to be associated with antibiotic resistance is the decrease in the virulence capabilities of the resistant strain. Such findings have been reported in the case of rifampicin-resistant and colistin-resistant strains, in which decrease in infective ability, quorum sensing and motility have been documented.",
            "score": 187.8690230846405
        },
        {
            "docid": "35672682_18",
            "document": "Antibiotic resistance in gonorrhea . \"N. gonorrhoeae\" has also shown resistance to the aminoglycoside class of antibiotics. These antibiotics bind to the 16s rRNA of the 30S subunit of the bacterial ribosome, thereby stopping transcription of the bacterial genome. Resistance appears to be acquired through porin-related mechanisms, much like the cephalosporin resistance mechanism. This mechanism would result in the access of the antibiotic to the bacterial cell being inhibited. There is a possibility of future enzymes (made by the bacterium) that will be able to denature and inactivate the aminoglycosides.",
            "score": 143.1487181186676
        },
        {
            "docid": "4427_3",
            "document": "Beta-lactam . The \u03b2-lactam ring is part of the core structure of several antibiotic families, the principal ones being the penicillins, cephalosporins, carbapenems, and monobactams, which are, therefore, also called \u03b2-lactam antibiotics. Nearly all of these antibiotics work by inhibiting bacterial cell wall biosynthesis. This has a lethal effect on bacteria, although any given bacteria population will typically contain a subgroup that is resistant to \u03b2-lactam antibiotics. Bacterial resistance occurs as a result of the expression of one of many genes for the production of \u03b2-lactamases, a class of enzymes that break open the \u03b2-lactam ring. More than 1,800 different \u03b2-lactamase enzymes have been documented in various species of bacteria. These enzymes vary widely in their chemical structure and catalytic efficiencies. When bacterial populations have these resistant subgroups, treatment with \u03b2-lactam can result in the resistant strain becoming more prevalent and therefore more virulent. \u03b2-lactam derived antibiotics can be considered as one of the most important antibiotic classes but prone to clinical resistance. \u03b2-lactam exhibits its antibiotic properties by imitating the naturally occurring d-Ala-d-Ala substrate for the group of enzymes known as penicillin-binding proteins (PBP), which have as function to cross-link the peptidoglycan part of the cell wall of the bacteria.",
            "score": 210.613654255867
        },
        {
            "docid": "44981660_7",
            "document": "Eleftheria terrae . \"E. terrae\"s production of teixobactin is prominent because recent tests have revealed that teixobactin binds differently than most normally used antibiotics which makes it harder for the bacteria being attacked to develop resistance. Experiments performed by Ling et al. have shown teixobactin is capable of binding to lipid precursors of peptidoglycan, which makes up part of bacterial cell walls. The results did not show any resistance to teixobactin in the organisms that were studied, including \"Staphylococcus aureus\" and \"Mycobacterium tuberculosis\". These findings indicate that teixobactin's target is not a protein, leading to the belief that the development of bacterial resistance to teixobactin is much less likely. These experiments also showed that teixobactin followed a similar mechanism of action as the antibiotic vancomycin that binds to the lipid II molecule in peptidoglycan precursors but, unlike vancomycin, teixobactin is capable of binding to modified lipid II molecules found in vancomycin resistant bacteria. Teixobactin's inhibition of peptidoglycan synthesis is further explained by Ling's finding of a buildup of undecaprenyl-N-acetylmuramic acid-pentapeptide, a crucial step in the biosynthesis of peptidoglycan. According to Ling's tests, teixobactin is capable of inhibiting peptidoglycan synthesis by binding to either lipid I, lipid II, and undecaprenyl pyrophosphate. Teixobactin also seemed to be specifically involved with peptidoglycan precursors rather than blocking enzyme activity.",
            "score": 175.1902562379837
        },
        {
            "docid": "1491100_29",
            "document": "Flavin adenine dinucleotide . New design of anti-bacterial medications is of continuing importance in scientific research as bacterial antibiotic resistance to common antibiotics increases. A specific metabolic protein that uses FAD (Complex II) is vital for bacterial virulence, and so targeting FAD synthesis or creating FAD analogs could be a useful area of investigation. Already, scientists have determined the two structures FAD usually assumes once bound: either an extended or a butterfly conformation, in which the molecule essentially folds in half, resulting in the stacking of the adenine and isoalloxazine rings. FAD imitators that are able to bind in a similar manner but do not permit protein function could be useful mechanisms of inhibiting bacterial infection. Alternatively, drugs blocking FAD synthesis could achieve the same goal; this is especially intriguing because human and bacterial FAD synthesis relies on very different enzymes, meaning that a drug made to target bacterial FAD synthase would be unlikely to interfere with the human FAD synthase enzymes.",
            "score": 132.2619503736496
        },
        {
            "docid": "14075884_2",
            "document": "23S ribosomal RNA . The 23S rRNA is a 2904 nt long (in \"E. coli\") component of the large subunit (50S) of the bacterial/archean ribosome. The ribosomal peptidyl transferase activity resides in domain V of this rRNA, and this domain is the most common binding site for antibiotics that inhibit translation. A well-known member of this antibiotic class, chloramphenicol, acts by inhibiting peptide bond formation, with recent 3D-structural studies showing two different binding sites depending on the species of ribosome. Linezolid and quinupristin-dalfopristin also bind to the 23S rRNA, and cross-resistance has been demonstrated between these antibiotics. Compared to 16S rRNA genes, 23S rRNA genes typically have higher sequence variations including insertions and/or deletions",
            "score": 162.02697372436523
        },
        {
            "docid": "24838_11",
            "document": "Peptidoglycan . Stage two occurs in the cytoplasmic membrane. It is in the membrane where a lipid carrier called bactoprenol carries peptidoglycan precursors through the cell membrane. Bactoprenol will attack the UDP-MurNAc penta, creating a PP-MurNac penta, which is now a lipid. UDP-GlcNAc is then transported to MurNAc, creating Lipid-PP-MurNAc penta-GlcNAc, a disaccharide, also a precursor to peptidoglycan. How this molecule is transported through the membrane is still not understood. However, once it is there, it is added to the growing glycan chain. The next reaction is known as tranglycosylation. In the reaction, the hydroxyl group of the GlcNAc will attach to the MurNAc in the glycan, which will displace the lipid-PP from the glycan chain. The enzyme responsible for this is transglycosylase. Some antibacterial drugs such as penicillin interfere with the production of peptidoglycan by binding to bacterial enzymes known as penicillin-binding proteins or DD-transpeptidases. Penicillin-binding proteins form the bonds between oligopeptide crosslinks in peptidoglycan. For a bacterial cell to reproduce through binary fission, more than a million peptidoglycan subunits (NAM-NAG+oligopeptide) must be attached to existing subunits. Mutations in genes coding for transpeptidases that lead to reduced interactions with an antibiotic are a significant source of emerging antibiotic resistance.",
            "score": 140.1014255285263
        },
        {
            "docid": "205627_18",
            "document": "Drug resistance . For antibiotic resistance, which represents a widespread problem nowadays, drugs designed to block the mechanisms of bacterial antibiotic resistance are used. For example, bacterial resistance against beta-lactam antibiotics (such as penicillins and cephalosporins) can be circumvented by using antibiotics such as nafcillin that are not susceptible to destruction by certain beta-lactamases (the group of enzymes responsible for breaking down beta-lactams). Beta-lactam bacterial resistance can also be dealt with by administering beta-lactam antibiotics with drugs that block beta-lactamases such as clavulanic acid so that the antibiotics can work without getting destroyed by the bacteria first. Recently, researchers have recognized the need for new drugs that inhibit bacterial efflux pumps, which cause resistance to multiple antibiotics such as beta-lactams, quinolones, chloramphenicol, and trimethoprim by sending molecules of those antibiotics out of the bacterial cell. Sometimes a combination of different classes of antibiotics may be used synergistically; that is, they work together to effectively fight bacteria that may be resistant to one of the antibiotics alone.",
            "score": 204.61322402954102
        },
        {
            "docid": "541592_10",
            "document": "Broad-spectrum antibiotic . After continued exposure to an antibiotic, bacteria may develop changes in their structure or function that make them resistant to the antibiotic. These resistant organisms will live, while the susceptible organisms will die, leaving the population of bacteria entirely resistant to a given antibiotics. For example, after the discovery of penicillin and its subsequent use to treat bacterial infections, bacteria were found to have begun producing an enzyme, penicillinase, which rendered the penicillin molecule inactive. In response to this newly-acquired resistance, newer penicillins were produced that could not be de-activated by penicillinases. This cycle of bacteria evolving resistance to antibiotics and necessitating the development of new antibiotics has been referred to as a \"bacterial arms race.\"",
            "score": 210.25289607048035
        },
        {
            "docid": "4152874_7",
            "document": "Penicillin binding proteins . There has been a great deal of research into PBPs because of their role in antibiotics and resistance. Bacterial cell wall synthesis and the role of PBPs in its synthesis is a very good target for drugs of selective toxicity because the metabolic pathways and enzymes are unique to bacteria. Resistance to antibiotics has come about through overproduction of PBPs and formation of PBPs that have low affinity for penicillins (among other mechanisms such as lactamase production). Research on PBPs has led to the discovery of new semi-synthetic \u03b2-lactams, wherein altering the side-chains on the original penicillin molecule has increased the affinity of PBPs for penicillin, and, thus, increased effectiveness in bacteria with developing resistance.",
            "score": 181.23836612701416
        },
        {
            "docid": "33032867_11",
            "document": "Discovery and development of cephalosporins . Although the mechanism of action for \u03b2-lactam antibiotics is not completely known they are believed to exert their mechanism of action by mimicking the structure of the transition state of the chemical reaction when the transpeptidase is bound to the D-alanyl-D-alanine sequence. These proteins are often referred to as penicillin binding proteins (PBP). Opening of the \u03b2-lactam ring by a serine residue in the enzyme binding site leads to covalent binding of the antibiotic molecule with the active site of the enzyme. The result is an inactive irreversibly bound enzyme-complex which is incapable of further cell wall synthesis and the cell will die from osmotic-lysis.",
            "score": 85.68296599388123
        },
        {
            "docid": "424484_7",
            "document": "Methicillin . Like other beta-lactam antibiotics, methicillin acts by inhibiting the synthesis of bacterial cell walls. It inhibits cross-linkage between the linear peptidoglycan polymer chains that make up a major component of the cell wall of gram-positive bacteria. It does this by binding to and competitively inhibiting the transpeptidase enzyme (also known as penicillin-binding proteins (PBPs)). These PBPs crosslink glycopeptides (\"-alanyl-alanine\"), forming the peptidoglycan cell wall. Methicillin and other \u03b2-lactam antibiotics are structural analogs of -alanyl-alanine, and the transpeptidase enzymes that bind to them are sometimes called penicillin-binding proteins (PBPs).",
            "score": 130.51800298690796
        },
        {
            "docid": "53416251_12",
            "document": "Moenomycin family antibiotics . The moenomycin family functions as an antibiotic by reversibly binding bacterial transglycosylases, essential enzymes that catalyze the extension of the glycan chain of the cell wall to form a stable peptidoglycan layer. The moenomycins mimic and thus compete with the natural substrate of the enzyme, inhibiting growth of the cell wall. Compromise of the wall results in leakage of cell contents, and ultimately cell death. The moenomycins are the only known active site inhibitors of these enzymes, which in lies their promise as human antibiotics given pathogenic bacteria have not yet widely evolved resistance.",
            "score": 143.54909467697144
        },
        {
            "docid": "28331039_2",
            "document": "New Delhi metallo-beta-lactamase 1 . New Delhi metallo-beta-lactamase 1 (NDM-1) is an enzyme that makes bacteria resistant to a broad range of beta-lactam antibiotics. These include the antibiotics of the carbapenem family, which are a mainstay for the treatment of antibiotic-resistant bacterial infections. The gene for NDM-1 is one member of a large gene family that encodes beta-lactamase enzymes called carbapenemases. Bacteria that produce carbapenemases are often referred to in the news media as \"superbugs\" because infections caused by them are difficult to treat. Such bacteria are usually susceptible only to polymyxins and tigecycline.",
            "score": 192.5118796825409
        },
        {
            "docid": "466746_17",
            "document": "Mycoplasma pneumoniae . The difficulty in eradicating \"Mycoplasma pneumoniae\" infections is due to the ability of the bacterium to persist within an individual, as well as the lack of cell wall in \"M. pneumoniae\", which renders multiple antibiotics directed at the bacterial cell wall ineffective in treating infections. \"M. pneumoniae\" therefore displays resistance to antimicrobials such as \u03b2-lactams, glycopeptides, sulfonamides, trimethoprim, polymixins, nalidixic acid, and rifampin. The majority of antibiotics used to treat \"M. pneumoniae\" infections are targeted at bacterial rRNA in ribosomal complexes, including macrolides, tetracycline, ketolides, and fluoroquinolone, many of which can be administered orally. Macrolides are capable of reducing hyperresponsiveness and protecting the epithelial lining from oxidative and structural damage, however they are capable only of inhibiting bacteria (bacteriostatic) and are not able to cause bacterial cell death. The most common macrolides used in the treatment of infected children in Japan are erythromycin and clarithromycin, which inhibit bacterial protein synthesis by binding 23S rRNA. Administration of antibiotics has been proven to reduce the longevity and intensity of \"M. pneumoniae\" infections in comparison to cases left untreated. Additionally, some high-dose steroid therapies have shown to reverse neurological effects in children with complicated infections. Antimicrobial drug resistance rates for \"Mycoplasma pneumoniae\" were determined in clinical specimens and isolates obtained during 2011\u20132012 in Ontario, Canada. Of 91 \"M. pneumoniae\" drug-resistant specimens, 11 (12.1%) carried nucleotide mutations associated with macrolide resistance in the 23S rRNA gene. None of the \"M. pneumoniae\" specimens were resistant to fluoroquinolones or tetracyclines.",
            "score": 224.18158388137817
        },
        {
            "docid": "722565_2",
            "document": "Ketolide . Ketolides are antibiotics belonging to the macrolide group. Ketolides are derived from erythromycin by substituting the cladinose sugar with a keto-group and attaching a cyclic carbamate group in the lactone ring. These modifications give ketolides much broader spectrum than other macrolides. Moreover, ketolides are effective against macrolide-resistant bacteria, due to their ability to bind at two sites at the bacterial ribosome as well as having a structural modification that makes them poor substrates for efflux-pump mediated resistance. Ketolides block protein synthesis by binding to ribosomal subunits and may also inhibit the formation of newly forming ribosomes. According to a recent study comparing the action of the classic macrolides erythromycin and azithromycin with ketolides, which are used to treat serious infections, the more powerful drugs (ketolides) were the more \"leaky\" in blocking the production of proteins. The researchers were surprised to discover that ketolides, which are known to be better antibiotics, allow for many more proteins to be made compared to the older, less efficient macrolides. As a result, it is now believed that allowing cells to make some proteins could be much more damaging for a microbe than not letting it make any proteins at all. The findings may point the way to better and more potent antibiotics.",
            "score": 248.8429777622223
        },
        {
            "docid": "39127620_5",
            "document": "Epimerox . No bacteria could be identified that were resistant to the compound (resistance frequency of <10). Thus, epimerox is an antibiotic with low resistance potential. Therefore, 2-epimerase is a new antibiotic target to which resistance is a rare event. 2-Epimerase was discovered as a target because it was one of the enzymes in the biosynthetic pathway for synthesizing an essential neutral polysaccharide in the cell wall of \"B. anthracis\" (Glu:Gal-\"N\"Ac:Man-\"N\"Ac at a 3:2:1 ratio). This polysaccharide is only found in \"B. anthracis\" and is the receptor for a bacteriophage lysin enzyme called PlyG, which is produced by the \u03b3-bacteriophage to release its progeny from infected \"B. anthracis\". For bacteriophage to survive they need to replicate inside a bacterial cell and release their progeny phage when they are assembled using their lysin. Since lysins from bacteriophage that infect Gram-positive bacteria must bind to a cell wall receptor to function, the enzymes have evolved over a billion years to identify substrate receptors in the bacterial cell wall that the bacteria cannot change easily. These substrates are either part of the peptidoglycan or sugars linked to it. Deletion of both 2-epimerase genes in \"B. anthracis\" is lethal to the bacterium.",
            "score": 175.64856147766113
        },
        {
            "docid": "12815929_2",
            "document": "\u0392-Lactamase inhibitor . Beta-lactamases are a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. They act by breaking the beta-lactam ring that allows penicillin-like antibiotics to work. Strategies for combating this form of resistance have included the development of new beta-lactam antibiotics that are more resistant to cleavage and the development of the class of enzyme inhibitors called beta-lactamase inhibitors. Although \u03b2-lactamase inhibitors have little antibiotic activity of their own, they prevent bacterial degradation of beta-lactam antibiotics and thus extend the range of bacteria the drugs are effective against.",
            "score": 172.2764277458191
        },
        {
            "docid": "36074373_2",
            "document": "Enzybiotics . Enzybiotics are an experimental antibiotic approach employing enzymes to combat pathogenic bacterial infections. The name is a combination of the words \"enzyme\" and \"antibiotics\" first coined in March 2001 by Nelson et al. Many of the enzymes used as enzybiotics are lysins, enzymes derived from bacterial viruses (or bacteriophages) used to release progeny bacteriophage from infected bacteria, though other natural or synthetic enzymes may be used.",
            "score": 111.65881061553955
        },
        {
            "docid": "52784_17",
            "document": "\u0392-lactam antibiotic . If the bacterium produces the enzyme \u03b2-lactamase or the enzyme penicillinase, the enzyme will hydrolyse the \u03b2-lactam ring of the antibiotic, rendering the antibiotic ineffective. (An example of such an enzyme is New Delhi metallo-beta-lactamase 1, discovered in 2009.) The genes encoding these enzymes may be inherently present on the bacterial chromosome or may be acquired via plasmid transfer (plasmid-mediated resistance), and \u03b2-lactamase gene expression may be induced by exposure to \u03b2-lactams.",
            "score": 115.76636385917664
        },
        {
            "docid": "28331039_5",
            "document": "New Delhi metallo-beta-lactamase 1 . Carbapenems are a class of beta-lactam antibiotics that are capable of killing most bacteria by inhibiting the synthesis of one of their cell wall layers. The carbapenems were developed to overcome antibiotic resistance mediated by bacterial beta-lactamase enzymes. However, the \"bla\" gene produces NDM-1, which is a carbapenemase beta-lactamase - an enzyme that hydrolyzes and inactivates these carbapenem antibiotics.",
            "score": 156.19034790992737
        },
        {
            "docid": "31640520_28",
            "document": "6-Deoxyerythronolide B synthase . Enzymes that act on the macrolide after it has been released and cyclized by DEBS are called tailoring enzymes. Many such enzymes are involved in the production of erythromycin from the final product of unmodified DEBS, 6-deoxyerythronolide B. Such classes of enzymes include mainly oxidoreductases and glycosyl transferases and are essential for the antibiotic activity of erythromycin. Thus far, few attempts have been made to modify tailoring pathways, however, the enzymes which participate in such pathways are currently being characterized and are of great interest. Studies are facilitated by their respective genes being located adjacent to the PKS genes, and many are therefore readily identifiable. There is no doubt that in the future, alteration of tailoring enzymes could produce many new and effective antimicrobials.",
            "score": 87.36838245391846
        },
        {
            "docid": "53416251_13",
            "document": "Moenomycin family antibiotics . The 25-carbon lipid tail confers to the moenomycins a detergent-like property that allows them to become incorporated into the cytoplasmic membrane of the target bacterial cell. This anchoring presents the oligosaccharide portion of the molecule to the transglycosylase where it can tightly and selectively bind the enzyme, inhibiting cell wall growth. This property however undermines their use in clinical settings. The amphiphilic nature of the moenomycins induce hemolytic activity, provide a long half-life in the blood stream, and creates a tendency to aggregate in aqueous solution. Comparison of moenomycins with an abridged isoprene chain of 10-carbons, show that the oligosaccharide can still tightly bind the enzyme active site, but \"in vivo\" the MIC significantly increases since the drug is unable to anchor itself to the cytoplasmic membrane and present its sugar moiety. Further studies are needed to determine the optimal length for favorable pharmacokinetic properties.",
            "score": 71.14847922325134
        },
        {
            "docid": "118212_46",
            "document": "Staphylococcus aureus . The treatment of choice for \"S. aureus\" infection is penicillin. An antibiotic derived from some \"Penicillium\" fungal species, penicillin inhibits the formation of peptidoglycan cross-linkages that provide the rigidity and strength in a bacterial cell wall. The four-membered \u03b2-lactam ring of penicillin is bound to enzyme DD-transpeptidase, an enzyme that when functional, cross-links chains of peptidoglycan that form bacterial cell walls. The binding of \u03b2-lactam to DD-transpeptidase inhibits the enzyme\u2019s functionality and it can no longer catalyze the formation of the cross-links. As a result, cell wall formation and degradation are imbalanced, thus resulting in cell death. In most countries, however, penicillin resistance is extremely common, and first-line therapy is most commonly a penicillinase-resistant \u03b2-lactam antibiotic (for example, oxacillin or flucloxacillin, both of which have the same mechanism of action as penicillin). Combination therapy with gentamicin may be used to treat serious infections, such as endocarditis, but its use is controversial because of the high risk of damage to the kidneys. The duration of treatment depends on the site of infection and on severity. Adjunctive rifampicin has been historically used in the management of \"S aureus\" bacteraemia, but randomised controlled trial evidence has shown this to be of no overall benefit over standard antibiotic therapy.",
            "score": 115.64565217494965
        },
        {
            "docid": "2515404_12",
            "document": "Production of antibiotics . Microorganisms used in fermentation are rarely identical to the wild type. This is because species are often genetically modified to yield the maximum amounts of antibiotics. Mutation is often used, and is encouraged by introducing mutagens such as ultraviolet radiation, x-rays or certain chemicals. Selection and further reproduction of the higher yielding strains over many generations can raise yields by 20-fold or more. Another technique used to increase yields is gene amplification, where copies of genes coding for enzymes involved in the antibiotic production can be inserted back into a cell, via vectors such as plasmids. This process must be closely linked with retesting of antibiotic production.",
            "score": 135.77389287948608
        },
        {
            "docid": "209023_12",
            "document": "Streptomycin . Streptomycin is a protein synthesis inhibitor. It binds to the small 16S rRNA of the 30S subunit of the bacterial ribosome, interfering with the binding of formyl-methionyl-tRNA to the 30S subunit. This leads to codon misreading, eventual inhibition of protein synthesis and ultimately death of microbial cells through mechanisms that are still not understood. Speculation on this mechanism indicates that the binding of the molecule to the 30S subunit interferes with 50S subunit association with the mRNA strand. This results in an unstable ribosomal-mRNA complex, leading to a frameshift mutation and defective protein synthesis; leading to cell death. Humans have ribosomes which are structurally different from those in bacteria, so the drug does not have this effect in human cells. At low concentrations, however, streptomycin only inhibits growth of the bacteria by inducing prokaryotic ribosomes to misread mRNA. Streptomycin is an antibiotic that inhibits both Gram-positive and Gram-negative bacteria, and is therefore a useful broad-spectrum antibiotic.",
            "score": 197.2182079553604
        },
        {
            "docid": "3119987_6",
            "document": "Ampicillin/sulbactam . Ampicillin/sulbactam is a combination of a \u03b2-lactam antibiotic and a \u03b2-lactamase inhibitor. Ampicillin works by binding to penicillin-binding proteins (PBPs) to inhibit bacterial cell wall synthesis. This causes disruption of the bacterial cell wall and leads to bacterial cell death. However, resistant pathogens may produce \u03b2-lactamase enzymes that can inactivate ampicillin through hydrolysis. This is prevented by the addition of sulbactam, which binds and inhibits the \u03b2-lactamase enzymes. It is also capable of binding to the PBP of Bacteroides fragilis and Acinetobacter spp., even when it is given alone. The activity of sulbactam against Acinetobacter spp. seen in in-vitro studies makes it distinctive compared to other \u03b2-lactamase inhibitors, such as tazobactam and clavulanic acid.",
            "score": 123.9502534866333
        },
        {
            "docid": "19200_5",
            "document": "Molecular biology . One of the most basic techniques of molecular biology to study protein function is molecular cloning. In this technique, DNA coding for a protein of interest is cloned using polymerase chain reaction (PCR), and/or restriction enzymes into a plasmid (expression vector). A vector has 3 distinctive features: an origin of replication, a multiple cloning site (MCS), and a selective marker usually antibiotic resistance. Located upstream of the multiple cloning site are the promoter regions and the transcription start site which regulate the expression of cloned gene. This plasmid can be inserted into either bacterial or animal cells. Introducing DNA into bacterial cells can be done by transformation via uptake of naked DNA, conjugation via cell-cell contact or by transduction via viral vector. Introducing DNA into eukaryotic cells, such as animal cells, by physical or chemical means is called transfection. Several different transfection techniques are available, such as calcium phosphate transfection, electroporation, microinjection and liposome transfection. The plasmid may be integrated into the genome, resulting in a stable transfection, or may remain independent of the genome, called transient transfection.",
            "score": 119.50911438465118
        },
        {
            "docid": "10852103_10",
            "document": "Acetyl\u2014CoA synthetase . The activity of the enzyme is controlled in several ways. The essential lysine residue in the active site plays an important role in regulation of activity. The lysine molecule can be deacetylated by another class of enzyme called sirtuins. In mammals, the cytoplasmic-nuclear synthetase (AceCS1) is activated by SIRT1 while the mitochondrial synthetase (AceCS2) is activated by SIRT3. This action increases activity of this enzyme. The exact location of the lysine residue varies between species, occurring at Lys-642 in humans, but is always present in the active site of the enzyme. Since there is an essential allosteric change that occurs with the binding of an AMP molecule, the presence of AMP can contribute to regulation of the enzyme. Concentration of AMP must be high enough so that it can bind in the allosteric binding site and allow the other substrates to enter the active site. Also, copper ions deactivate acetyl Co-A synthetase by occupying the proximal site of the A-cluster active site, which prevents the enzyme from accepting a methyl group to participate in the Wood-Ljungdahl Pathway. The presence of all the reactants in the proper concentration is also needed for proper functioning as in all enzymes.  Acetyl\u2014CoA synthetase is also produced when it is needed for fatty acid synthesis, but, under normal conditions, the gene is inactive and has certain transcriptional factors that activate transcription when necessary. In addition to sirtuins, protein deacetylase (AcuC) also can modify acetyl\u2014CoA synthetase at a lysine residue. However, unlike sirtuins, AcuC does not require NAD+ as a cosubstrate.",
            "score": 51.605433225631714
        },
        {
            "docid": "2160013_13",
            "document": "Regulatory enzyme . Here, the active and inactive form of the enzymes are altered due to covalent modification of their structures which is catalysed by other enzymes. This type of regulation consists of the addition or elimination of some molecules which can be attached to the enzyme protein. The most important groups that work as modifiers are phosphate, methyl, uridine, adenine and adenosine diphosphate ribosyl. These groups are joined to or eliminated from the protein by other enzymes. The most remarkable covalent modification is phosphorylation. Serine, Threonine and Tyrosine are common amino acids that participate in covalent modifications and are used to control enzyme\u2019s catalytic activities. Kinase and phosphatases are commonly known enzymes that affect these modifications, which result in shifting of conformational states of the binding affinity to substrate.",
            "score": 63.9174268245697
        },
        {
            "docid": "21958_9",
            "document": "Nucleolus . Transcription of rRNA yields a long precursor molecule (45S pre-rRNA) which still contains the ITS and ETS. Further processing is needed to generate the 18S RNA, 5.8S and 28S RNA molecules. In eukaryotes, the RNA-modifying enzymes are brought to their respective recognition sites by interaction with guide RNAs, which bind these specific sequences. These guide RNAs belong to the class of small nucleolar RNAs (snoRNAs) which are complexed with proteins and exist as small-nucleolar-ribonucleoproteins (snoRNPs). Once the rRNA subunits are processed, they are ready to be assembled into larger ribosomal subunits. However, an additional rRNA molecule, the 5S rRNA, is also necessary. In yeast, the 5S rDNA sequence is localized in the intergenic spacer and is transcribed in the nucleolus by RNA pol.",
            "score": 70.57571697235107
        },
        {
            "docid": "19372852_4",
            "document": "MecA (gene) . The \"mecA\" gene does not allow the ringlike structure of penicillin-like antibiotics to bind to the enzymes that help form the cell wall of the bacterium (transpeptidases), and hence the bacteria is able to replicate as normal. mecA is located on the staphylococcal chromosome cassette \"mec\". The gene encodes the protein PBP2A (penicillin binding protein 2A). PBP2A has a low affinity for beta-lactam antibiotics such as methicillin and penicillin. This enables transpeptidase activity in the presence of beta-lactams, preventing them from inhibiting cell wall synthesis.",
            "score": 149.72513437271118
        }
    ],
    "r": [
        {
            "docid": "1914_48",
            "document": "Antimicrobial resistance . Antibiotic action against a pathogen can be seen as an environmental pressure. Those bacteria with a mutation that allows them to survive will reproduce, pass the trait to their offspring, which leads to the microevolution of a fully resistant colony. Chromosomal mutations providing antibiotic resistance benefit the bacteria but also confer a cost of fitness. For example, a ribosomal mutation may protect a bacterial cell by changing the binding site of an antibiotic but will also slow protein synthesis. manifesting, in slower growth rate.",
            "score": 257.6019592285156
        },
        {
            "docid": "4421942_3",
            "document": "TetR . Tetracycline (tc) is a broad family of antibiotics to which bacteria have evolved resistance. Tc normally kills bacteria by binding to the bacterial ribosome and halting protein synthesis. The expression of tc resistance genes is regulated by Tet Repressor Protein. More specifically, TetR represses the expression of TetA, a membrane protein that pumps out substances toxic to the bacteria, by binding the TetA operator. In tc resistant bacteria, TetA will pump out tc before it can bind to the ribosome. Therefore, TetR may have an important role in helping scientists to better understand mechanisms of antibiotic resistance and how to treat antibiotic resistant bacteria. TetR is one of many proteins in the TetR protein family, which is so named because TetR is the most well characterized member.",
            "score": 256.64862060546875
        },
        {
            "docid": "1914_3",
            "document": "Antimicrobial resistance . Resistance arises through one of three mechanisms: natural resistance in certain types of bacteria, genetic mutation, or by one species acquiring resistance from another. All classes of microbes can develop resistance. Fungi develop antifungal resistance. Viruses develop antiviral resistance. Protozoa develop antiprotozoal resistance, and bacteria develop antibiotic resistance. Resistance can appear spontaneously because of random mutations. However, extended use of antimicrobials appears to encourage mutations which can render antimicrobials ineffective. Preventive measures include only using antibiotics when needed, thereby stopping misuse of antibiotics or antimicrobials. Narrow-spectrum antibiotics are preferred over broad-spectrum antibiotics when possible, as effectively and accurately targeting specific organisms is less likely to cause resistance. For people who take these medications at home, education about proper use is essential. Health care providers can minimize spread of resistant infections by use of proper sanitation and hygiene, including handwashing and disinfecting between patients, and should encourage the same of the patient, visitors, and family members. Rising drug resistance is caused mainly by use of antimicrobials in humans and other animals, and spread of resistant strains between the two. Growing resistance has also been linked to dumping of inadequately treated effluents from the pharmaceutical industry, especially in countries where bulk drugs are manufactured. Antibiotics increase selective pressure in bacterial populations, causing vulnerable bacteria to die; this increases the percentage of resistant bacteria which continue growing. Even at very low levels of antibiotic, resistant bacteria can have a growth advantage and grow faster than vulnerable bacteria. With resistance to antibiotics becoming more common there is greater need for alternative treatments. Calls for new antibiotic therapies have been issued, but new drug development is becoming rarer.",
            "score": 251.65830993652344
        },
        {
            "docid": "722565_2",
            "document": "Ketolide . Ketolides are antibiotics belonging to the macrolide group. Ketolides are derived from erythromycin by substituting the cladinose sugar with a keto-group and attaching a cyclic carbamate group in the lactone ring. These modifications give ketolides much broader spectrum than other macrolides. Moreover, ketolides are effective against macrolide-resistant bacteria, due to their ability to bind at two sites at the bacterial ribosome as well as having a structural modification that makes them poor substrates for efflux-pump mediated resistance. Ketolides block protein synthesis by binding to ribosomal subunits and may also inhibit the formation of newly forming ribosomes. According to a recent study comparing the action of the classic macrolides erythromycin and azithromycin with ketolides, which are used to treat serious infections, the more powerful drugs (ketolides) were the more \"leaky\" in blocking the production of proteins. The researchers were surprised to discover that ketolides, which are known to be better antibiotics, allow for many more proteins to be made compared to the older, less efficient macrolides. As a result, it is now believed that allowing cells to make some proteins could be much more damaging for a microbe than not letting it make any proteins at all. The findings may point the way to better and more potent antibiotics.",
            "score": 248.8429718017578
        },
        {
            "docid": "55868631_20",
            "document": "List of antibiotic resistant bacteria . Although mutation alone plays a huge role in the development of antibiotic resistance, a 2008 study found that high survival rates after exposure to antibiotics could not be accounted for by mutation alone. This study focused on the development of resistance in E. coli to three antibiotic drugs: ampicillin, tetracycline, and nalidixic acid. The researchers found that some antibiotic resistance in E. coli developed because of epigenetic inheritance rather than by direct inheritance of a mutated gene. This was further supported by data showing that reversion to antibiotic sensitivity was relatively common as well. This could only be explained by epigenetics. Epigenetics is a type of inheritance in which gene expression is altered rather than the genetic code itself. There are many modes by which this alteration of gene expression can occur, including methylation of DNA and histone modification; however, the important point is that both inheritance of random mutations and epigenetic markers can result in the expression of antibiotic resistance genes.",
            "score": 234.38864135742188
        },
        {
            "docid": "5745363_5",
            "document": "Evolutionary pressure . Drug resistance in bacteria is an example of an outcome of natural selection. When a drug is used on a species of bacteria, those that cannot resist die and do not produce offspring, while those that survive potentially pass on the resistance gene to the next generation (vertical gene transmission). The resistance gene can also be passed on to one bacterium by another of a different species (horizontal gene transmission). Because of this, the drug resistance increases over generations. For example, in hospitals, environments are created where pathogens such as \"C\". \"difficile\" have developed a resistance to antibiotics. Antibiotic resistance is made worse by the misuse of antibiotics. Antibiotic resistance is encouraged when antibiotics are used to treat non-bacterial diseases, and when antibiotics are not used for the prescribed amount of time or in the prescribed dose. Antibiotic resistance may arise out of standing genetic variation in a population or de novo mutations in the population. Either pathway could lead to antibiotic resistance, which may be a form of evolutionary rescue.",
            "score": 230.56198120117188
        },
        {
            "docid": "25162957_7",
            "document": "Transposons as a genetic tool . Insertional inactivation focuses on suppressing the expression of a gene by disrupting its sequence with an insertion. When additional nucleotides are inserted near or into a locus, the locus can suffer a frameshift mutation that could prevent it from being properly expressed into polypeptide chain. Transposon-based Insertional inactivation is considered for medical research from suppression of antibiotic resistance in bacteria to the treatment of genetic diseases. In the treatment of genetic diseases, the insertion of a transposon into deleterious gene locus of organism's genome would misalign the locus sequence, truncating any harmful proteins formed and rendering them non-functional. Alternatively insertional inactivation could be used to suppress genes that express antibiotic-resistance in bacteria.,",
            "score": 229.5392608642578
        },
        {
            "docid": "9028799_58",
            "document": "Bacteria . Bacterial infections may be treated with antibiotics, which are classified as bacteriocidal if they kill bacteria, or bacteriostatic if they just prevent bacterial growth. There are many types of antibiotics and each class inhibits a process that is different in the pathogen from that found in the host. An example of how antibiotics produce selective toxicity are chloramphenicol and puromycin, which inhibit the bacterial ribosome, but not the structurally different eukaryotic ribosome. Antibiotics are used both in treating human disease and in intensive farming to promote animal growth, where they may be contributing to the rapid development of antibiotic resistance in bacterial populations. Infections can be prevented by antiseptic measures such as sterilising the skin prior to piercing it with the needle of a syringe, and by proper care of indwelling catheters. Surgical and dental instruments are also sterilised to prevent contamination by bacteria. Disinfectants such as bleach are used to kill bacteria or other pathogens on surfaces to prevent contamination and further reduce the risk of infection.",
            "score": 229.20750427246094
        },
        {
            "docid": "13520743_22",
            "document": "Functional cloning . One of the ongoing challenges of treating bacterial infections is antibiotic resistance which commonly arises when patients do not take their full treatment of medication and hence allow bacteria to develop resistance to antibiotics over time. To understand how to combat antibiotic resistance it is important to understand how the bacterial genome is evolving and changing in healthy individuals with no recent usage of antibiotics to provide a baseline. Using a functional cloning-based technique, DNA isolated from human microflora were cloned into expression vectors in \"Escherichia coli\". Afterwards, antibiotics were applied as a screen. If a plasmid contained a gene insert that provided antibiotic resistance the cell survived and was selected on the plate. If the insert provided no resistance, the cell died and did not form a colony. Based on selection of cell colonies that survived, a better picture of genetic factors contributing to antibiotic resistance were pieced together. Most of the resistance genes that were identified were previously unknown. By using a functional cloning-based technique one is able to elucidate genes giving rise to antibiotic resistance to better understand treatment for bacterial infections.",
            "score": 227.79469299316406
        },
        {
            "docid": "1041856_19",
            "document": "Porin (protein) . However, due to selective pressure, bacteria can develop resistance through mutations in the porin gene. The mutations may lead to a loss of porins, resulting in the antibiotics having a lower permeability or being completely excluded from transport. These changes have contributed to the global emergence of antibiotic resistance, and an increase in mortality rates from infections.",
            "score": 225.37930297851562
        },
        {
            "docid": "466746_17",
            "document": "Mycoplasma pneumoniae . The difficulty in eradicating \"Mycoplasma pneumoniae\" infections is due to the ability of the bacterium to persist within an individual, as well as the lack of cell wall in \"M. pneumoniae\", which renders multiple antibiotics directed at the bacterial cell wall ineffective in treating infections. \"M. pneumoniae\" therefore displays resistance to antimicrobials such as \u03b2-lactams, glycopeptides, sulfonamides, trimethoprim, polymixins, nalidixic acid, and rifampin. The majority of antibiotics used to treat \"M. pneumoniae\" infections are targeted at bacterial rRNA in ribosomal complexes, including macrolides, tetracycline, ketolides, and fluoroquinolone, many of which can be administered orally. Macrolides are capable of reducing hyperresponsiveness and protecting the epithelial lining from oxidative and structural damage, however they are capable only of inhibiting bacteria (bacteriostatic) and are not able to cause bacterial cell death. The most common macrolides used in the treatment of infected children in Japan are erythromycin and clarithromycin, which inhibit bacterial protein synthesis by binding 23S rRNA. Administration of antibiotics has been proven to reduce the longevity and intensity of \"M. pneumoniae\" infections in comparison to cases left untreated. Additionally, some high-dose steroid therapies have shown to reverse neurological effects in children with complicated infections. Antimicrobial drug resistance rates for \"Mycoplasma pneumoniae\" were determined in clinical specimens and isolates obtained during 2011\u20132012 in Ontario, Canada. Of 91 \"M. pneumoniae\" drug-resistant specimens, 11 (12.1%) carried nucleotide mutations associated with macrolide resistance in the 23S rRNA gene. None of the \"M. pneumoniae\" specimens were resistant to fluoroquinolones or tetracyclines.",
            "score": 224.18157958984375
        },
        {
            "docid": "15464966_19",
            "document": "Pathogenic bacteria . Bacterial infections may be treated with antibiotics, which are classified as bacteriocidal if they kill bacteria or bacteriostatic if they just prevent bacterial growth. There are many types of antibiotics and each class inhibits a process that is different in the pathogen from that found in the host. For example, the antibiotics chloramphenicol and tetracyclin inhibit the bacterial ribosome but not the structurally different eukaryotic ribosome, so they exhibit selective toxicity. Antibiotics are used both in treating human disease and in intensive farming to promote animal growth. Both uses may be contributing to the rapid development of antibiotic resistance in bacterial populations. Phage therapy can also be used to treat certain bacterial infections.",
            "score": 222.2068328857422
        },
        {
            "docid": "1910927_3",
            "document": "Repressor lexA . DNA damage can be inflicted by the action of antibiotics, bacteriophages and UV light. Of potential clinical interest is the induction of the SOS response by antibiotics, such as ciprofloxacin. Bacteria require topoisomerases such as DNA gyrase or topoisomerase IV for DNA replication. Antibiotics such as ciprofloxacin are able to prevent the action of these molecules by attaching themselves to the gyrase - DNA complex, leading to replication fork stall and the induction of the SOS response. The expression of error-prone polymerases under the SOS response increases the basal mutation rate of bacteria. While mutations are often lethal to the cell, they can also enhance survival. In the specific case of topoisomerases, some bacteria have mutated one of their amino acids so that the ciprofloxacin can only create a weak bond to the topoisomerase. This is one of the methods that bacteria use to become resistant to antibiotics. Ciprofloxacin treatment can therefore potentially lead to the generation of mutations that may render bacteria resistant to ciprofloxacin. In addition, ciprofloxacin has also been shown to induce via the SOS response dissemination of virulence factors and antibiotic resistance determinants, as well as the activation of integron integrases, potentially increasing the likelihood of acquisition and dissemination of antibiotic resistance by bacteria.",
            "score": 219.30418395996094
        },
        {
            "docid": "1805_19",
            "document": "Antibiotic . The emergence of resistance of bacteria to antibiotics is a common phenomenon. Emergence of resistance often reflects evolutionary processes that take place during antibiotic therapy. The antibiotic treatment may select for bacterial strains with physiologically or genetically enhanced capacity to survive high doses of antibiotics. Under certain conditions, it may result in preferential growth of resistant bacteria, while growth of susceptible bacteria is inhibited by the drug. For example, antibacterial selection for strains having previously acquired antibacterial-resistance genes was demonstrated in 1943 by the Luria\u2013Delbr\u00fcck experiment. Antibiotics such as penicillin and erythromycin, which used to have a high efficacy against many bacterial species and strains, have become less effective, due to the increased resistance of many bacterial strains.",
            "score": 218.937744140625
        },
        {
            "docid": "620229_6",
            "document": "SOS response . Recent research has shown that the SOS pathway may be essential in the acquisition of bacterial mutations which lead to resistance to some antibiotic drugs. The increased rate of mutation during the SOS response is caused by three low-fidelity DNA polymerases: Pol II, Pol IV and Pol V. Researchers are now targeting these proteins with the aim of creating drugs that prevent SOS repair. By doing so, the time needed for pathogenic bacteria to evolve antibiotic resistance could be extended, and thus improve the long term viability of some antibiotic drugs.",
            "score": 218.8693389892578
        },
        {
            "docid": "37627534_5",
            "document": "Mary Barber (bacteriologist) . Barber's research was focused on the \"staphylococcus\" bacterium as well as various aspects of antibiotics, especially development of penicillin-resistant bacteria. Her first scientific paper was published in 1937 and concerned meningitis caused by the Listeria bacterium. In 1947, she published her best-known work, on penicillin resistance in \"staphylocci\", proving that the bacteria were becoming more resistant to the drug over time, using the new technique of phage typing. She found that this was because bacteria with mutations that caused them to synthesize a penicillin-destroying enzyme were selected during treatment with antibiotics, leading to rapid spread of a single antibiotic-resistant strain throughout the hospital. Between 1948 and 1958, her focus shifted to cross-infection by \"Staphylococcus\" in hospitals, which she found to be caused by penicilin-resistant bacteria and the nurses became nasal carriers soon after working on the wards. After she returned to BPMS (British Postgraduate Medical School) in 1958, she expanded upon this work, making a clear case for limiting antibiotic use and combining drugs for maximum effect and minimal increases in drug resistance; these studies were carried out at St. Thomas' Hospital. The policies implemented as a result of her work caused antibiotic resistance observed in the hospital to drop dramatically. After her successful publications, Barber was hired by the Medical Research Council to study semisynthetic penicillin, cephalosporin, fucidin, lincomycin, and pristinamycin. In 1963, she published \"Antibiotic and Chemotherapy\" with L. P. Garrod, an encyclopedic work on the characteristics and medical uses of various antibiotics. That same year, Barber was appointed a professor; in 1965 she was elected to the Royal College of Physicians.",
            "score": 218.3989715576172
        },
        {
            "docid": "4106560_12",
            "document": "Emerging infectious disease . Methicillin-resistant Staphylococcus aureus (MRSA) evolved from Methicillin-susceptible Staphylococcus aureus (MSSA) otherwise known as common \"S. aureus\". Many people are natural carriers of \"S. aureus\", without being affected in any way. MSSA was treatable with the antibiotic methicillin until it acquired the gene for antibiotic resistance. Though genetic mapping of various strains of MRSA, scientists have found that MSSA acquired the mecA gene in the 1960s, which accounts for its pathogenicity, before this it had a predominantly commensal relationship with humans. It is theorized that when this \"S. aureus\" strain that had acquired the mecA gene was introduced into hospitals, it came into contact with other hospital bacteria that had already been exposed to high levels of antibiotics. When exposed to such high levels of antibiotics, the hospital bacteria suddenly found themselves in an environment that had a high level of selection for antibiotic resistance, and thus resistance to multiple antibiotics formed within these hospital populations. When \"S. aureus\" came into contact with these populations, the multiple genes that code for antibiotic resistance to different drugs were then acquired by MRSA, making it nearly impossible to control. It is thought that MSSA acquired the resistance gene through the horizontal gene transfer, a method in which genetic information can be passed within a generation, and spread rapidly through its own population as was illustrated in multiple studies. Horizontal gene transfer speeds the process of genetic transfer since there is no need to wait an entire generation time for gene to be passed on. Since most antibiotics do not work on MRSA, physicians have to turn to alternative methods based in Darwinian medicine. However prevention is the most preferred method of avoiding antibiotic resistance. By reducing unnecessary antibiotic use in human and animal populations, antibiotics resistance can be slowed.",
            "score": 214.11927795410156
        },
        {
            "docid": "1672551_26",
            "document": "Concentrated animal feeding operation . Antibiotics are used heavily in CAFOs to both treat and prevent illness in individual animals as well as groups. The close quarters inside CAFOs promote the sharing of pathogens between animals and thus, the rapid spread of disease. Even if their stock are not sick, CAFOs will incorporate low doses of antibiotics into feed \u201cto reduce the chance for infection and to eliminate the need for animals to expend energy fighting off bacteria, with the assumption that saved energy will be translated into growth\u201d. This practice is an example of a non-therapeutic use of antibiotics. Such antibiotic use is thought to allow animals to grow faster and bigger, consequently maximizing production for that CAFO. Regardless, the World Health Organization has recommended that the non-therapeutic use of antibiotics in animal husbandry be reevaluated, as it contributes to the overuse of antibiotics and thus the emergence of resistant bacteria that can spread to humans. When bacteria naturally occurring in the animals\u2019 environment and/or body are exposed to antibiotics, natural selection results in bacteria, who have genetic variations that protect them from the drugs, to survive and spread their advantageously resistant traits to other bacteria present in the ecosystem. This is how the problem of antimicrobial resistance increases with the continued use of antibiotics by CAFOs. This is of concern to public health because resistant bacteria generated by CAFOs can be spread to the surrounding environment and communities via waste water discharge or aerosolization of particles.",
            "score": 212.4366455078125
        },
        {
            "docid": "40364158_11",
            "document": "Antibiotic use in livestock . The use of antibiotics to increase the growth of pigs is the most studied in livestock. This use for growth rather than disease prevention is referred to as subtherapeutic antibiotic use. Studies have shown that administering low doses of antibiotics in livestock feed improves growth rate, reduces mortality and morbidity, and improves reproductive performance. It is estimated that over one-half of the antibiotics produced and sold in the United States is used as a feed additive. Although it is still not completely understood why and how antibiotics increase the growth rate of pigs, possibilities include metabolic effects, disease control effects, and nutritional effects. While subtherapeutic use has many benefits for raising swine, there is growing concern that this practice leads to increased antibiotic resistance in bacteria. Antibiotic resistance occurs when bacteria are resistant to one or more microbial agents that are usually used to treat infection. There are three stages in the possible emergence and continuation of antibiotic resistance: genetic change, antibiotic selection, and spread of antibiotic resistance.",
            "score": 211.56385803222656
        },
        {
            "docid": "4427_3",
            "document": "Beta-lactam . The \u03b2-lactam ring is part of the core structure of several antibiotic families, the principal ones being the penicillins, cephalosporins, carbapenems, and monobactams, which are, therefore, also called \u03b2-lactam antibiotics. Nearly all of these antibiotics work by inhibiting bacterial cell wall biosynthesis. This has a lethal effect on bacteria, although any given bacteria population will typically contain a subgroup that is resistant to \u03b2-lactam antibiotics. Bacterial resistance occurs as a result of the expression of one of many genes for the production of \u03b2-lactamases, a class of enzymes that break open the \u03b2-lactam ring. More than 1,800 different \u03b2-lactamase enzymes have been documented in various species of bacteria. These enzymes vary widely in their chemical structure and catalytic efficiencies. When bacterial populations have these resistant subgroups, treatment with \u03b2-lactam can result in the resistant strain becoming more prevalent and therefore more virulent. \u03b2-lactam derived antibiotics can be considered as one of the most important antibiotic classes but prone to clinical resistance. \u03b2-lactam exhibits its antibiotic properties by imitating the naturally occurring d-Ala-d-Ala substrate for the group of enzymes known as penicillin-binding proteins (PBP), which have as function to cross-link the peptidoglycan part of the cell wall of the bacteria.",
            "score": 210.6136474609375
        },
        {
            "docid": "541592_10",
            "document": "Broad-spectrum antibiotic . After continued exposure to an antibiotic, bacteria may develop changes in their structure or function that make them resistant to the antibiotic. These resistant organisms will live, while the susceptible organisms will die, leaving the population of bacteria entirely resistant to a given antibiotics. For example, after the discovery of penicillin and its subsequent use to treat bacterial infections, bacteria were found to have begun producing an enzyme, penicillinase, which rendered the penicillin molecule inactive. In response to this newly-acquired resistance, newer penicillins were produced that could not be de-activated by penicillinases. This cycle of bacteria evolving resistance to antibiotics and necessitating the development of new antibiotics has been referred to as a \"bacterial arms race.\"",
            "score": 210.2528839111328
        },
        {
            "docid": "28352410_2",
            "document": "Plasmid-mediated resistance . Plasmid-mediated resistance is the transfer of antibiotic resistance genes which are carried on plasmids. The plasmids can be transferred between bacteria within the same species or between different species via conjugation. Plasmids often carry multiple antibiotic resistance genes, contributing to the spread of multidrug-resistance (MDR). Antibiotic resistance mediated by MDR plasmids severely limits the treatment options for the infections caused by Gram-negative bacteria, especially \"Enterobacteriaceae\" family. The global spread of MDR plasmids has been enhanced by selective pressure from antibiotic usage in human and veterinary medicine.",
            "score": 209.3585968017578
        },
        {
            "docid": "1914_50",
            "document": "Antimicrobial resistance . Bacteria\u00a0can develop\u00a0antibiotic\u00a0resistance. Recent findings show no necessity of large populations of bacteria for the appearance of antibiotic resistance. Small populations of \"E. coli\" in an antibiotic gradient can become resistant. Any heterogeneous environment with respect to nutrient and antibiotic gradients may facilitate antibiotic resistance in small bacterial populations. Researchers hypothesize that the mechanism of resistance development is based on four SNP mutations in the genome of \"E. coli\" produced by the gradient of antibiotic.",
            "score": 208.08030700683594
        },
        {
            "docid": "33532401_6",
            "document": "Subtherapeutic antibiotic use in swine . Bacterial antibiotic resistance is a process that can occur when bacteria are exposed to STA administration. When a population of bacteria that resides in a hog are exposed to a particular antibiotic for growth promotant purposes, the bacteria that are susceptible to the drug die while the organisms that are resistant will not be affected and will continue to replicate, resulting in a higher proportion of resistant organisms. It has been shown that resistance to antibiotics develops in animals that are fed subtherapeutic doses of antibiotics for growth promoting purposes. Certain bacteria that have the potential to cause human illness, such as Salmonella, that naturally reside in the swine gastrointestinal tracts are constantly exposed to antibiotics. With time, these bacteria become resistant to that class of antibiotics. There is great concern regarding the probability of subtherapeutic antibiotic use in swine causing treatment failures in human medicine.",
            "score": 206.28021240234375
        },
        {
            "docid": "40364158_47",
            "document": "Antibiotic use in livestock . Around 70% of all antibiotics administered are used for livestock. Some drugs are used in livestock feed to prevent illnesses and or increase growth rates, but others are used as injection to treat illnesses to prevent death. The use of antibiotics in livestock can be harmful to humans because it can create an antibiotic resistant bacteria in humans that can be transferred through several different ways such as: raw meats, consumption of meats, as well as ingestion through airborne bacteria. Waste from food-producing animals can also contain antibiotic-resistant bacteria and is sometimes stored in lagoons. This waste is often sprayed as fertilizer and can thus contaminate crops and water with the antibiotic-resistant bacteria. Although antibiotic use in livestock can be harmful to humans, most see it as a necessary evil to prevent disease and death in out livestock. Antibiotic resistance makes humans resistant to certain types of drugs for different diseases, as well as makes it harder for them to fight off infections.",
            "score": 205.99850463867188
        },
        {
            "docid": "205627_3",
            "document": "Drug resistance . The development of antibiotic resistance in particular stems from the drugs targeting only specific bacterial molecules (almost always proteins). Because the drug is \"so\" specific, any mutation in these molecules will interfere with or negate its destructive effect, resulting in antibiotic resistance. Furthermore there is mounting concern over the abuse of antibiotics in the farming of livestock, which in the European Union alone accounts for three times the volume dispensed to humans \u2013 leading to development of super-resistant bacteria.",
            "score": 205.88050842285156
        },
        {
            "docid": "2459654_30",
            "document": "Pseudomonas aeruginosa . One of the most worrisome characteristics of \"P. aeruginosa\" is its low antibiotic susceptibility, which is attributable to a concerted action of multidrug efflux pumps with chromosomally encoded antibiotic resistance genes (e.g., \"mexAB\", \"mexXY\", etc.) and the low permeability of the bacterial cellular envelopes. In addition to this intrinsic resistance, \"P. aeruginosa\" easily develops acquired resistance either by mutation in chromosomally encoded genes or by the horizontal gene transfer of antibiotic resistance determinants. Development of multidrug resistance by \"P. aeruginosa\" isolates requires several different genetic events, including acquisition of different mutations and/or horizontal transfer of antibiotic resistance genes. Hypermutation favours the selection of mutation-driven antibiotic resistance in \"P. aeruginosa\" strains producing chronic infections, whereas the clustering of several different antibiotic resistance genes in integrons favors the concerted acquisition of antibiotic resistance determinants. Some recent studies have shown phenotypic resistance associated to biofilm formation or to the emergence of small-colony variants may be important in the response of \"P. aeruginosa\" populations to antibiotics treatment.",
            "score": 205.62289428710938
        },
        {
            "docid": "424464_2",
            "document": "Linezolid . Linezolid is an antibiotic used for the treatment of infections caused by Gram-positive bacteria that are resistant to other antibiotics. Linezolid is active against most Gram-positive bacteria that cause disease, including streptococci, vancomycin-resistant enterococci (VRE), and methicillin-resistant \"Staphylococcus aureus\" (MRSA). The main uses are infections of the skin and pneumonia although it may be used for a variety of other infections including drug resistant tuberculosis. It is used either by injection into a vein or by mouth. Linezolid is a member of the oxazolidinone class of medications. When given for short periods, linezolid is a relatively safe antibiotic. It can be used in people of all ages and in people with liver disease or poor kidney function. Common side effects with short-term use include headache, diarrhea, rash, and nausea. Serious side effects may include serotonin syndrome, bone marrow suppression, and high blood lactate levels, particularly when used for more than two weeks. If used for longer periods it may cause nerve damage, including optic nerve damage, which may be irreversible. As a protein synthesis inhibitor, it affects the ability of bacteria to produce protein. This either stops growth or results in bacterial death. Although many antibiotics work this way, the exact mechanism of action of linezolid appears to be unique in that it blocks the start of protein production, rather than one of the later steps. As of 2014 bacterial resistance to linezolid has remained low. Linezolid was discovered in the mid 1990s and was approved for commercial use in 2000. It is on the World Health Organization's List of Essential Medicines, the most effective and safe medicines needed in a health system. Linezolid is available as a generic medication. The wholesale cost in the developing world is about US$ 2.90 USD per day while that in the United States as of 2016 is about US$13.79 per day. It appears to be more cost-effective than alternatives such as vancomycin, mostly because of the ability to switch from intravenous use to administration by mouth sooner. The main use of linezolid is the treatment of severe infections caused by anaerobic Gram-positive bacteria that are resistant to other antibiotics; it should not be used against bacteria that are sensitive to drugs with a narrower spectrum of activity, such as penicillins and cephalosporins. In both the popular press and the scientific literature, linezolid has been called a \"reserve antibiotic\"\u2014one that should be used sparingly so that it will remain effective as a drug of last resort against potentially intractable infections.",
            "score": 205.30113220214844
        },
        {
            "docid": "21147_34",
            "document": "Natural selection . Natural selection is seen in action in the development of antibiotic resistance in microorganisms. Since the discovery of penicillin in 1928, antibiotics have been used to fight bacterial diseases. The widespread misuse of antibiotics has selected for microbial resistance to antibiotics in clinical use, to the point that the methicillin-resistant \"Staphylococcus aureus\" (MRSA) has been described as a \"superbug\" because of the threat it poses to health and its relative invulnerability to existing drugs. Response strategies typically include the use of different, stronger antibiotics; however, new strains of MRSA have recently emerged that are resistant even to these drugs. This is an evolutionary arms race, in which bacteria develop strains less susceptible to antibiotics, while medical researchers attempt to develop new antibiotics that can kill them. A similar situation occurs with pesticide resistance in plants and insects. Arms races are not necessarily induced by man; a well-documented example involves the spread of a gene in the butterfly \"Hypolimnas bolina\" suppressing male-killing activity by \"Wolbachia\" bacteria parasites on the island of Samoa, where the spread of the gene is known to have occurred over a period of just five years",
            "score": 204.96717834472656
        },
        {
            "docid": "339961_13",
            "document": "Pseudomonas . \"Pseudomonas aeruginosa\" is increasingly recognized as an emerging opportunistic pathogen of clinical relevance. One of its most worrying characteristics is its low antibiotic susceptibility. This low susceptibility is attributable to a concerted action of multidrug efflux pumps with chromosomally encoded antibiotic resistance genes (e.g., \"mexAB-oprM\", \"mexXY\", etc.,) and the low permeability of the bacterial cellular envelopes. Besides intrinsic resistance, \"P. aeruginosa\" easily develops acquired resistance either by mutation in chromosomally encoded genes or by the horizontal gene transfer of antibiotic resistance determinants. Development of multidrug resistance by \"P. aeruginosa\" isolates requires several different genetic events that include acquisition of different mutations and/or horizontal transfer of antibiotic resistance genes. Hypermutation favours the selection of mutation-driven antibiotic resistance in \"P. aeruginosa\" strains producing chronic infections, whereas the clustering of several different antibiotic resistance genes in integrons favours the concerted acquisition of antibiotic resistance determinants. Some recent studies have shown phenotypic resistance associated to biofilm formation or to the emergence of small-colony-variants, which may be important in the response of \"P. aeruginosa\" populations to antibiotic treatment.",
            "score": 204.9453887939453
        },
        {
            "docid": "205627_18",
            "document": "Drug resistance . For antibiotic resistance, which represents a widespread problem nowadays, drugs designed to block the mechanisms of bacterial antibiotic resistance are used. For example, bacterial resistance against beta-lactam antibiotics (such as penicillins and cephalosporins) can be circumvented by using antibiotics such as nafcillin that are not susceptible to destruction by certain beta-lactamases (the group of enzymes responsible for breaking down beta-lactams). Beta-lactam bacterial resistance can also be dealt with by administering beta-lactam antibiotics with drugs that block beta-lactamases such as clavulanic acid so that the antibiotics can work without getting destroyed by the bacteria first. Recently, researchers have recognized the need for new drugs that inhibit bacterial efflux pumps, which cause resistance to multiple antibiotics such as beta-lactams, quinolones, chloramphenicol, and trimethoprim by sending molecules of those antibiotics out of the bacterial cell. Sometimes a combination of different classes of antibiotics may be used synergistically; that is, they work together to effectively fight bacteria that may be resistant to one of the antibiotics alone.",
            "score": 204.61322021484375
        },
        {
            "docid": "38156540_40",
            "document": "Seafood mislabelling . The overuse of antibiotics can create antibiotic-resistant bacteria. Antibiotic-resistant bacteria can spontaneously arise when selective pressure to survive results in changes to the DNA sequence of a bacteria allowing that bacteria to survive antibiotic treatments. Because some of the same antibiotics are used to treat fish that are used to treat human disease, pathogenic bacteria causing human disease can also become resistant to antibiotics as a result of treatment of fish with antibiotics. For this reason, the overuse of antibiotics in treatment of fish aquaculture (among other agricultural uses) could create public health issues.",
            "score": 204.37469482421875
        }
    ]
}